MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY

Brandon S. Imber, M. Lia Palomba, Carl J. DeSelm, Connie Lee Batlevi, Parastoo B. Dahi, Sergio Giralt, Ariela Noy, J.H. Park, Craig S. Sauter, Michael Scordo,

Hematological Oncology · 2019 · 15 citations · 0 references

Concepts

Abstract

Introduction: CD19-targeted chimeric antigen receptor T cell (CAR T) therapies have remarkable overall response rates (ORR) for relapsed diffuse large B cell lymphoma (DLBCL). There is strong rationale to use a radiotherapy (RT) bridge during cellular manufacturing including palliation, local control and cytoreduction with limited count impact. Recent data from our institution suggests RT may also augment an immune response and sensitize antigen negative cells to CAR-mediated death. This series details our early experience using RT conditioning. Methods: 11 patients (median age 61 years) with DLBCL (n = 8) or transformed follicular lymphoma (n = 3) were analyzed. Overall, patients had a median of 2 prior therapies (range 1-8) including 3 with auto transplant, 3 with distant RT and 1 with CAR T infusion. Several CAR products were used, including axicabtagene ciloleucel (n = 6), JCAR017 (n = 3, per NCT02631044), tisagenlecleucel (n = 1) and EGFRt/19-28z/4-1BBL “armored” CAR (n = 1, per NCT03085173). Most patients began RT (n = 8) post apheresis with median duration between RT and CAR infusion of 20d (range 13-80). The most common RT regimen (n = 6) was 20 Gy in 5 fractions (range 20-47 Gy) but 2 received our pre-transplant regimen of 30 Gy in 20 BID fractions. None received concurrent chemotherapy with RT but one had a cycle post RT and pre CAR. All had cy/flu lymphodepletion. PET response was evaluated by Lugano criteria. Results: 2 patients (18%) had limited stage PET avid disease at RT and were treated comprehensively pre-CAR. The remaining 9 were advanced stage, and were treated palliatively to limited sites. Irradiated sites included the neck (n = 4), pelvis/groin (n = 3), intraabdominal (n = 2) and extremity (n = 2). Most (n = 9) had intensity modulated RT. RT fields were large (median planning treatment volume of 887 cc, range 163-1641). Post RT PET interpretation was challenging given a short interval since RT completion (median 11d) but of 8 evaluable patients, many (n = 6, 75%) had partial response (PR). Though locally controlled, most (n = 7, 88%) had out of field progressive disease (PD) pre CAR. Of 7 evaluable patients post CAR T, no severe adverse events in the RT field were noted, 5 had cytokine release syndrome (n = 1 grade 3) and 4 had neurotoxicity (n = 3 grade 3). At day 30, ORR was 100%; of 6 evaluable patients, 5 had complete metabolic response (CMR) and 1 had near CMR. Of the 5 evaluable patients at day 90, 3 (60%) had continued CMR and the other 2 (40%) had PD and subsequently died from DLBCL. One relapsed at 95d post armored CAR both in and out of the RT field, and the other relapsed at 64d post JCAR017 primarily out of field. Keywords: diffuse large B-cell lymphoma (DLBCL); immune system; salvage treatment. Disclosures: Palomba, M: Consultant Advisory Role: Merck, Pharmacyclics; Stock Ownership: Seres (spouse); Honoraria: Flagship Ventures, Novartis, Evelo, Seres, Jazz Pharmaceuticals, Therakos, Amgen, Merck (all spouse); Other Remuneration: Royalties: Seres, Juno (both spouse). DeSelm, C: Consultant Advisory Role: Merck, Pharmacyclics; Stock Ownership: Seres (spouse); Honoraria: Flagship Ventures, Novartis, Evelo, Seres, Jazz Pharmaceuticals, Therakos, Amgen, Merck (all spouse); Other Remuneration: Royalties: Seres, Juno (both spouse). Batlevi, C: Consultant Advisory Role: Life Sci, GLG, Juno/Celgene, Seattle Genetics; Honoraria: Dava Oncology; Research Funding: Janssen, Novartis, Epizyme, Xynomics, Bayer, Juno, BMS. Giralt, S: Consultant Advisory Role: Amgen, Actinuum, Celgene, Johnson & Johnson, Jazz Pharmaceuticals, Takeda, Novartis, Kite, Spectrum Pharma; Research Funding: Amgen, Actinuum, Celgene, Johnson & Johnson, Miltenyi, Takeda. Shah, G: Research Funding: Janssen and Amgen. Sadelain, M: Consultant Advisory Role: Berkeley Lights; Research Funding: Juno Therapeutics, Fate Therapeutics, Atara Biotherapeutics, Takeda. Perales, M: Consultant Advisory Role: Servier, Medigene, MolMed and NexImmune; Honoraria: Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, and Takeda; Research Funding: Incyte and Miltenyi Biotec.